Hepatocellular carcinoma historical perspective

Jump to navigation Jump to search

Hepatocellular carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes of Hepatocellular carcinoma

Differentiating Hepatocellular carcinoma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic study of choice

History and symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatocellular carcinoma historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatocellular carcinoma historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatocellular carcinoma historical perspective

CDC on Hepatocellular carcinoma historical perspective

Hepatocellular carcinoma historical perspective in the news

Blogs on Hepatocellular carcinoma historical perspective

Directions to Hospitals Treating Hepatocellular carcinoma

Risk calculators and risk factors for Hepatocellular carcinoma historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]

Overview

IN 1910 Eggel did a survey on literature from all over the world on hepatocellular carcinoma and demonstrated its gross anatomical classification. HCC was first noted to be associated with Hepatitis B infection in 1970. Kyoto University Japan, developed a technique to use the right lobe of the donor liver. Total of 48 adult HCC cases underwent transplant until April 2002 with good outcomes. The ongoing advancement in harvesting embryonic stem cells for tissue production strongly predicts that the liver transplantation may someday be replaced by stem cell therapy. A number of techniques have evolved for the use of in vitro and in vivo produced hepatocytes derived from stem cells for liver transplantation.

Historical Perspective

  • In 1910 Eggel in Germany did a survey on literature from all over the world for hepatocellular carcinoma (HCC) autopsies out of which he discovered only 163 cases and demonstrated its gross anatomical classification. It was then speculated that the European numbers were far higher than those outside Europe.[1]
  • In 1911, Yamagiwa suggested a new classification system based on the cell of origin and divided hepatobiliary cancers into hepatocellular cancer and cholangiocellular cancer, with the proposed terminology of hepatoma and cholangioma.[2][3]
  • In 1951, Berman drew the world's attention towards the extremely high incidence of HCC among young Mozambican males which was over 500 times more common in this population as among the northern European counterparts. Higginson followed up and studied the global epidemiology and confirmed Berman’s report.
  • Edmondson with Peters and Simson, Steiner, Nakashima, unequivocally presented that there is a huge regional variation in pathology and that the HCC does not represent a single disease. Livers affected with HCC weighed more than 4 kg at autopsy among the South African blacks and less than 2 kg in the Japanese population.[4][5][6][7]
  • Hepatocellular carcinoma was first noted to be associated with hepatitis B infection in 1970.[8]
  • Okuda K, Fujimoto I, Hanai A and Urano Y published a study in Japan in 1987 describing the varying trends in the incidence of hepatocellular carcinoma in Japan stating the increase in HCC cases with chronic hepatitis C infection with cirrhosis were reported in majority compared to those with cirrhosis and hepatitis B infection.[9]
  • In another study by Colombo et al published in 1991, it was noted that patients with liver cirrhosis belonging to western countries were at a substantial risk for hepatocellular carcinoma compared to the Asian population, with an annual incidence rate of 3 percent.[10]
  • Data obtained from northern European countries was obtained, where the lancet used for smallpox vaccination was changed for every child in the distant past, it seemed that smallpox vaccination rather than intramuscular injection of vaccine was a significant iatrogenic factor for hepatitis C infection (HCV infection) and HCV-associated HCC in those countries where the same lancet was used repeatedly for vaccination.[3]
  • In 1965 another study was done by the Japanese surgeons, pathologists, and radiologists recruiting patients from 829 participating institutes with more than 17,500 cases of primary liver malignancies. The data was compiled annually leading towards progress in the diagnosis and management of HCC. A broad clinical and pathologic study of small and early HCC was carried out by the Japanese hepatologists and radiologists and an early detection (screening) program was developed in which ultrasound and alpha-fetoprotein (AFP) measurement are carried out at regular intervals, which lead to an early detection international strategy for diagnosis and management of HCC.[11]
  • Percutaneous ethanol injection (PEI) therapy and lipiodol-assisted chemoembolisation was adopted in Japan in 1983.
  • Kyoto University Japan, developed a technique to use the right lobe of the donor liver. Total of 48 adult HCC cases underwent transplant until April 2002 with good outcomes.
  • The ongoing advancement in harvesting embryonic stem cells for tissue production strongly predicts that the liver transplantation may someday be replaced by stem cell therapy. A number of techniques have evolved for the use of in vitro and in vivo produced hepatocytes derived from stem cells for liver transplantation.

References

  1. Eggel H, Ueber das prim&-e Carcinom der Leber. Beitr z path Ana z allg Path 1910;30:506-604
  2. Yamagiwa K. Zum Kenntniss des prim%ren parenchymatosen Leberkarzinoms (“Hepatoma”). Virchows Arch Path Anat 1911;203:75-131.
  3. 3.0 3.1 Okuda K (2002). "Hepatocellular carcinoma--history, current status and perspectives". Dig Liver Dis. 34 (9): 613–6. PMID 12405244.
  4. Berman C. Primary carcinoma of the Liver. London: Higginson Lewis; 19.5 1.
  5. Okuda K, Peters RL, Simson IW. Gross anatomical features of hepatocellular carcinoma from three disparate geographic areas Proposal of new classification. Cancer 1984;54:2165-73.
  6. Steiner PE. Cancer of the liver and cirrhosis in trans-Saharan Africa and the United States of America. Cancer 1960;13:1085-166.
  7. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K, Ikari T (1983). "Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years". Cancer. 51 (5): 863–77. PMID 6295617.
  8. Di Bisceglie AM (2009). "Hepatitis B and hepatocellular carcinoma". Hepatology. 49 (5 Suppl): S56–60. doi:10.1002/hep.22962. PMC 3047495. PMID 19399807.
  9. Okuda K, Fujimoto I, Hanai A, Urano Y (1987). "Changing incidence of hepatocellular carcinoma in Japan". Cancer Res. 47 (18): 4967–72. PMID 3040235.
  10. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N (1991). "Hepatocellular carcinoma in Italian patients with cirrhosis". N. Engl. J. Med. 325 (10): 675–80. doi:10.1056/NEJM199109053251002. PMID 1651452.
  11. Okuda K, The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Cancer 1980;45:2663-9.



Template:WikiDoc Sources